Loading clinical trials...
Loading clinical trials...
Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Multiple Myeloma
Conditions
Interventions
PHE885
Locations
9
United States
Uni of Chi Medi Ctr Hema and Onco
Chicago, Illinois, United States
Beth Israel Deaconess Medical Cente
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Ramat Gan, Israel
Start Date
July 23, 2020
Primary Completion Date
April 29, 2025
Completion Date
April 29, 2025
Last Updated
May 20, 2025
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions